Appearance of the slow Ca conductance in myotubes from mutant mice with "muscular dysgenesis"

Molecular origin of the L-type Ca2+ current of skeletal muscle myotubes selectively deficient in dihydropyridine receptor beta1a subunit

The origin of Ibetanull, the Ca2+ current of myotubes from mice lacking the skeletal dihydropyridine receptor (DHPR) beta1a subunit, was investigated. The density of Ibetanull was similar to that of Idys, the Ca2+ current of myotubes from dysgenic mice lacking the skeletal DHPR alpha1S subunit (-0.6 +/- 0.1 and -0.7 +/- 0.1 pA/pF, respectively). However, Ibetanull activated at significantly more positive potentials. The midpoints of the GCa-V curves were 16.3 +/- 1.1 mV and 11.7 +/- 1.0 mV for Ibetanull and Idys, respectively. Ibetanull activated significantly more slowly than Idys. At +30 mV, the activation time constant for Ibetanull was 26 +/- 3 ms, and that for Idys was 7 +/- 1 ms. The unitary current of normal L-type and beta1-null Ca2+ channels estimated from the mean variance relationship at +20 mV in 10 mM external Ca2+ was 22 +/- 4 fA and 43 +/- 7 fA, respectively. Both values were significantly smaller than the single-channel current estimated for dysgenic Ca2+ channels, which was 84 +/- 9 fA under the same conditions. Ibetanull and Idys have different gating and permeation characteristics, suggesting that the bulk of the DHPR alpha1 subunits underlying these currents are different. Ibetanull is suggested to originate primarily from Ca2+ channels with a DHPR alpha1S subunit. Dysgenic Ca2+ channels may be a minor component of this current. The expression of DHPR alpha1S in beta1-null myotubes and its absence in dysgenic myotubes was confirmed by immunofluorescence labeling of cells.

Myotube driven myogenic recruitment of cells during in vitro myogenesis

Muscular dysgenesis (mdg) is a recessive lethal mutation in the mouse which drastically affects skeletal muscle development during embryonic life. Physiologically, the disease is characterized by a complete paralysis resulting from a lack of excitation-contraction coupling. Existing electrophysiological, biochemical, and genetic evidence shows that mdg/mdg mice express a basic alteration of L-type voltage-sensitive Ca2+ channels in skeletal muscle. Studies on mdg/mdg myotubes in primary culture have shown that +/+ fibroblasts or +/+ Schwann cells may fuse with them and correct their functional deficiency by genetic complementation. As the spontaneous formation of heterocaryons is thought to be an exclusive property of myoblasts, we asked whether fibroblasts may have changed their properties before fusion occurred. We used primary cells issued from sciatic nerves dissected from newborn transgenic mice carrying the pHuDes1-nls-LacZ transgene (Des-LacZ cells) as non-muscle cells. These cells were mainly fibroblasts (80%) positive for Thy1.1 and Schwann cells positive for S100. The cultures were negative for myogenic markers (desmin, troponin T), did not form myotubes long-term, and did not display significant activation of the muscle reporter gene (pHuDes1-nls-LacZ). After a few days in coculture with dysgenic or normal myotubes, the muscle reporter gene (beta-galactosidase) was detected both within dysgenic myotubes, correlating with the restoration of normal contractile activity, and normal myotubes. As well as confirming that fusion takes place, this shows that Des-LacZ cells nuclei incorporated into recipient myotubes express their own myogenic genes. Moreover, individual mononucleated Des-LacZ cells expressing beta-galactosidase were observed, indicating that myogenic genes were being expressed before fusion. This suggests a mechanism of myotube driven myogenic recruitment of cells during the in vitro myogenesis. Analysis of the distribution of the induced Des-LacZ cells (positive for beta-galactosidase) in compartmentalized muscle cocultures showed that in the presence of dysgenic myotubes, these cells were equally distributed in both myotube free and enriched areas, whereas in the presence of normal myotubes, the positive cells remained in close vicinity of the myotubes. This difference could be explained by the fact that the dysgenic phenotype might include release of the induction process from its normal controls. Our results are consistent with the idea of a transcellular mechanism triggering myogenic differentiation in non-muscle cells, and that myotubes themselves are able to drive myogenic recruitment of cells during the in vitro myogenesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of SR33557 on intramembrane charge movement in normal and 'muscular dysgenesis' mouse skeletal muscle cells

It has been reported that the indolizinsulphone SR33557, which binds to a site on the alpha 1 subunit of the dihydropyridine receptor, blocks both L-type calcium channel activity and contraction in skeletal muscle. Moreover, we know that charge movement plays a key role in the mechanism of excitation-contraction coupling and in controlling the opening of L-type calcium channels. We demonstrate here that SR33557 reduces intramembrane charge movement in skeletal muscle from normal mice with an IC50 of approximately 10 nM. The drug does not completely inhibit charge movement since approximately 20% of total charge movement persists even in the presence of 30 microM SR33557. However, the SR33557-sensitive charge component is more important than the dihydropyridine-sensitive one. Surprisingly, SR33557 also reduces intramembrane charge movement in dysgenic myotubes which are characterized by a very strong reduction of the number of dihydropyridine binding sites. In these muscles, 10 microM SR33557 reduces approximately 40% of total charge movement. These observations suggest the presence of a new component of charge movement which is sensitive to SR33557 but insensitive to nifedipine. This component is also present in dysgenic myotubes, and it could be produced by the lower molecular weight alpha 1 subunit described by Malouf, N. N., McMahon, D. K., Hainsworth, C. N. and Kay, B. K. (1992) (Neuron, 8, 899-906).

Charge movement and Ca2+ release in normal and dysgenic foetal myotubes

Intramembrane charge movement and Ca2+ release from sarcoplasmic reticulum was studied in foetal skeletal muscle cells from normal and mutant mice with 'muscular dysgenesis' (mdg/mdg). It was shown that: 1) unlike normal myotubes, in dysgenic myotubes membrane depolarization did not evoke calcium release from the sarcoplasmic reticulum; 2) when all ionic currents are pharmacologically suppressed, membrane depolarization produced an asymmetric intramembrane charge movement in both normal and dysgenic myotubes. The relationship between the membrane potential and the amount of charge movement in these muscles could be expressed by a two-state Boltzmann equation; 3) the maximum amount of charge movement associated with depolarization (Qon max) in normal and in dysgenic myotubes was 6.3 +/- 1.4 nC/microF (n = 6) and 1.7 +/- 0.3 nC/microF (n = 6) respectively; 4) nifedipine (1-20 microM) applied to the bath reduced Qon max by about 40% in normal muscle cells. In contrast, the drug had no significant effect on the charge movement of dysgenic myotubes; and 5) the amount of nifedipine-resistant charge movement in normal and in dysgenic myotubes was 3.5 nC/microF (n = 3) and 1.7 nC/microF 1 maximum (n = 3), respectively.

Barium currents in developing skeletal muscle cells of normal and mutant mice foetuses with 'muscular dysgenesis'

The ontogenesis of Ca channel activities was studied in the developing myotubes of normal mice and mutant mice foetuses with 'Muscular Dysgenesis'. The ionic current through Ca channels was measured with Ba2+ as charge carrier using the whole cell clamp technique. All dissociated myotubes from foetuses (14th to 18th day of gestation) showed two distinct inward Ba currents: a low threshold, transient current (T-type) and a high threshold sustained current. In normal myotubes, T-type current density increased from the 14th day to the 16th day of gestation. After day 16, T-type current density decreased gradually until birth. Similar changes in T-type current density were observed in developing dysgenic myotubes where the current density was about 40% of that measured in normal myotubes throughout the prenatal period studied. The high threshold sustained current (L-type current) density increased gradually with age in normal myotubes while absent in dysgenic muscle. The latter, regardless of age, showed a high threshold current (Idys) which is distinct from the L-type current. Idys density did not change during the prenatal myogenesis period studied.

Muscle fibers from dysgenic mouse in vivo lack a surface component of peripheral couplings

We have studied the structure of developing normal and dysgenic (mdg/mdg) mouse muscle fibers in vivo, with special attention to the components of the junctions between the sarcoplasmic reticulum and either the surface membrane or the transverse tubules. Triads and dyads are rare in dysgenic muscle fibers, but have apparently normal disposition of feet and calsequestrin. Peripheral couplings in normal developing muscle fibers have junctional tetrads in their surface membrane in association with the junctional feet. Muscle fibers in dysgenic mice lack junctional tetrads. This provides indirect evidence for the identification of the components of junctional tetrads with dihydropyridine receptors, which are known to be absent in dysgenic muscle fibers.

Contractions of dysgenic skeletal muscle triggered by a potentiated, endogenous calcium current

The dihydropyridine (DHP) receptor of normal skeletal muscle is hypothesized to function as the voltage sensor for excitation-contraction (E-C) coupling, and also as the calcium channel underlying a slowly activating, DHP-sensitive current (termed ICa-s). Skeletal muscle from mice with muscular dysgenesis lacks both E-C coupling and ICa-s. However, dysgenic skeletal muscle does express a small DHP-sensitive calcium current (termed ICa-dvs) which is kinetically and pharmacologically distinct from ICa-s. We have examined the ability of ICa-dys, or the DHP receptor underlying it, to couple depolarization and contraction. Under most conditions ICa-dys is small (approximately 1 pA/pF) and dysgenic myotubes do not contract in response to sarcolemmal depolarization. However, in the combined presence of the DHP agonist Bay K 8644 (1 microM) and elevated external calcium (10 mM), ICa-dys is strongly potentiated and some dysgenic myotubes contract in response to direct electrical stimulation. These contractions are blocked by removing external calcium, by adding 0.5 mM cadmium to the bath, or by replacing Bay K 8644 with the DHP antagonist (+)-PN 200-110. Only myotubes having a density of ICa-dys greater than approximately 4 pA/pF produce detectible contractions, and the strength of contraction is positively correlated with the density of ICa-dys. Thus, unlike the contractions of normal myotubes, the contractions of dysgenic myotubes require calcium entry. These results demonstrate that the DHP receptor underlying ICa-dys is unable to function as a "voltage sensor" that directly couples membrane depolarization to calcium release from the sarcoplasmic reticulum.

Reduced intramembrane charge movement in the dysgenic skeletal muscle cell

Intramembrane charge movement in skeletal muscle cells has been proposed to underlie the process leading to Ca release from the sarcoplasmic reticulum. A number of recent studies suggest that the dihydropyridine receptor located in the transverse-tubular membrane is responsible for the generation of intramembrane charge movement. The skeletal muscle cell of the mutant mouse with "Muscular Dysgenesis" is characterized by absence of excitation-contraction coupling. Here we investigated the charge movement in freshly dissociated skeletal muscle cells from dysgenic mice. In 9 out of 34 dysgenic mouse cells the charge movement was completely absent, in the remaining cells the charge movement was never more than 30% of control. The amount of maximum charge movement (Qmax) in mutant muscle cells was less than 30% of Qmax in normal muscle. Nifedipine, a dihydropyridine derivative, reduced the amount of charge movement in normal muscle cells but it was less effective on charge movement in mutant muscle cells. We conclude that there is an alteration of nifedipine-sensitive charge movement in the skeletal muscle cells from the mutant mice.